###### Strengths and limitations of this study

-   A prospective study over a period of 3 years and inclusion of all patients, irrespective of their age and sex, strengthens the representativeness of the results and obviates seasonal variations.

-   Data-collecting tools were same at both study hospitals and the staff who collected the data were trained by the same person at both locations to minimise variances.

-   An observational non-interventional study design might have minimised the effect on the prescribers of being observed and audited.

-   All possible efforts were made to minimise the risk of missing data by continuous monitoring and cross-checking of the data. However, some data---for example, a few diagnoses, might have been lost during translation from analogue to digital records.

-   A large proportion of patients were categorised as belonging to the suspected bacterial diagnosis groups. Some of these diagnoses might have been categorised as non-bacterial if the aetiology had been confirmed by microbiology reports. This could have contributed to even higher antibiotic prescribing rates in the non-bacterial diagnoses group. However, owing to the absence of confirmed aetiology and the observational design of the study this was not possible.

Background {#s1}
==========

Increasing morbidity and mortality due to infectious diseases, despite the availability of lifesaving antibiotics, is an alarming global situation.[@R1] The incidence of mortality due to infections is higher in low- and middle-income countries than in high-income countries.[@R2] The World Health Organization (WHO) has reported a high burden of communicable diseases in India and infections are responsible for 28% of the total mortality in the country.[@R5] [@R6] Additionally, antibiotic resistance in India is reported to be high. However, figures cannot be generalised to all Indian settings as the bacterial resistance patterns vary widely between its regions and settings and most studies so far have been relatively limited.[@R7]

Over- and underuse of antibacterial agents is a global concern. It results in unnecessary treatment costs, is a potential risk for the development of antibiotic resistance and results in side effects such as antibiotic-associated diarrhoea caused by *Clostridium difficile* or gastroenteritis.[@R8] According to a report, the global consumption of antibiotics increased by 36% between 2000 and 2010; five countries---Brazil, Russia, India, China and South Africa---accounted for 76% of this increase.[@R9] Despite the paucity of studies that describe antibiotic prescribing in India, Van Boeckel *et al*[@R9] presented India at the top of the list of antibiotic consumption with 12.9×10^9^ units in 2010, where one unit indicates a pill, capsule or ampoule.[@R1] On the one hand, this increase might mean that sections of the population that previously had no access to antibiotics can now access them, but on the other, the fact that antibiotic resistance is a consequence of antibiotic use cannot be ignored.[@R10]

It is thus imperative to map local prescribing patterns of antibiotics in order to examine the need for improvement and to counter the consequences of their inappropriate prescription. The Indian private sector is the major healthcare provider but little is known about its prescribing patterns.[@R11]

Objectives {#s2}
==========

The study was conducted to present, analyse and compare antibiotic prescribing to inpatients enrolled for the most common non-bacterial diagnoses at the medicine departments of a teaching (TH) and a non-teaching hospital (NTH) in central India.

Methods {#s3}
=======

Study design {#s3a}
------------

A cross-sectional observational design was used.

Setting {#s3b}
-------

The study was conducted at the medicine departments of two tertiary care hospitals (one TH and one NTH) from the private sector in Ujjain district, India, both of which are run by the same trust. The TH is located in a rural area of Ujjain district and had 570 beds at the time of the study. The NTH is located in the central part of Ujjain city and had 350 beds at the time of the study. The TH provides medical services, including medical treatment and free-of-charge medicines, to all patients, whereas the NTH charges for the medical facilities on a 'no profit--no loss' basis. Patients at the NTH have to buy prescribed medicines from the pharmacies inside or outside the hospital. The physicians at the TH are paid a salary and have no direct contact with sales representatives of pharmaceutical companies. Furthermore, the management at the TH is responsible for the purchase and supply of the drugs.

The hospital level essential medicine list was available in written form at the TH but no specific implementation activities were conducted during the study period. Local prescribing guidelines were not present at any of the hospitals. Almost all physicians practising at the NTH also undertook private practice and could be easily contacted by representatives of pharmaceutical companies. Payments of the physicians at the NTH increase above normal according to the number of patients they admit to the hospital and the number of visits they make to inpatients. Both the TH and the NTH are tertiary care hospitals with a number of specialty departments, such as paediatrics, obstetrics and gynaecology, surgery, orthopaedics, pulmonary medicine and so on, which treat specific patients. For example, patients presenting with symptoms related to lungs and chest (other than heart) visit the pulmonary medicine department. A well-equipped microbiology laboratory was present to process the samples free of cost for all patients from the TH and with nominal charges for those from the NTH.

Participants {#s3c}
------------

### Inclusion and exclusion criteria {#s3c1}

Patients who stayed for at least one night at medicine departments of either of the two hospitals were considered as inpatients and included in the study. Patients who had incomplete records or were admitted to the medical intensive care units within the medicine departments were not included in the analysis. Treatment recommendations, including dose and frequency, differ for patients less than 15 years of age and the defined daily dose (DDD) measurement is not applicable to them, thus they were also excluded.[@R15]

### Variables {#s3c2}

Patient information was analysed for age, sex, diagnosis, duration of hospital stay, if they received antibiotic treatment and duration of antibiotic treatment. Prescriptions were analysed for the type of antibiotics prescribed, their dose and frequency. The antibiotics were classified according to the Anatomical Therapeutic Chemical (ATC) classification of the WHO Collaborating Centre for Drug Statistics Methodology (WHOCC).[@R16] DDDs were calculated for all prescribed antibiotics.[@R16] DDD is a technical unit used for comparison and is the average daily dose of a specific drug for its main indication in adults.[@R15] Fixed-dose combinations (FDCs) of antibiotics that did not have an ATC code assigned by WHOCC were assigned the code 'J01RA\*' according to Sharma *et al*.[@R17] FDCs that did not have a DDD were assigned one by examining the constituents and the proportions in which they were found in one unit dose. The DDD was then calculated on the basis of the number of units and converted to a dose in grams. The total number of antibiotics prescribed during a hospital stay was counted for each patient and was designated 'prescribing occasions'.

The National List of Essential Medicines of India (NLEMI) is based on the WHO List of Essential Medicines (WHOLEM) and adapted to the spread of disease in India.[@R18] These lists serve as guidelines to promote the prescription of safe, cheap and effective drugs to the population.[@R18] [@R19] Adherence to these lists was evaluated for all prescriptions.

### Data sources and considerations {#s3c3}

The data collection process is described in detail elsewhere.[@R13] [@R14] In brief, the study was conducted prospectively between 1 April 2008 and 31 March 2011. Patient throughput in the TH and the NTH amounted to 29 026 and 41 561 patients, respectively. The data were manually collected by the nurses using a specially designed form attached to the patient\'s file at the medicine department of the TH and the NTH. All patients were included to minimise the possibility of selection bias. Every admission in the department was considered as a new patient. The nurses and new recruits were trained regularly for the data collection by the last author (MS). The data collection form was updated daily based on a patient\'s day-to-day progress. All notes written in the patient files by the treating consultant were recorded and included for the analysis. It was possible that a patient could have more than one diagnosis. Therefore all indications, diagnoses and/or symptoms recorded in the patient files were transferred to the data collection form. The data were translated to digital data files using Epidata software 3.1 (<http://www.epidata.dk/download.php>) and Microsoft Excel. Two specifically trained data entry operators translated the diagnoses in accordance with the 'International Classification of Diseases' (ICD-10 codes) and the generic names of the prescribed antibiotics were translated to WHO-assigned ATC codes and DDDs per day.[@R15] [@R20] [@R21]

In order to exclude all cases of clinically suspected bacterial infection and following the aim of the study, best possible efforts were made to distinguish those patients who had any indications, even for secondary antibiotic prophylaxis, from those who did not.[@R22] The patients were categorised into three main groups using the diagnoses registered in the patient files and the ICD-10 codes: group (a) cardiovascular diseases, (b) non-bacterial fevers and (c) all diagnoses other than group (a) and (b), including all types of bacterial infection. Sixty-seven per cent of patients in the TH and 75% in the NTH were included in group (c). All cases of chronic obstructive pulmonary disease (COPD) were also included in group (c). Although the aetiology of the disease was seldom specified in the records, these patients with COPD should receive less restricted antibiotic treatment.

Groups (a) and (b) were selected for a detailed study of antibiotic prescribing for non-bacterial diagnoses in accordance with the study aim. In group (a), hypertension, acute myocardial infarction and valvular heart disease were the most common diagnoses. In group (b) different types of malaria and cases of viral fever (ICD code-B34.9) were included. These non-bacterial fevers were common in both study settings. It has previously been reported that a large number of antibiotics are prescribed to patients with malaria or viral fever in malaria endemic countries like Uganda ([figure 1](#BMJOPEN2016012974F1){ref-type="fig"}).[@R25] Moreover, groups (a) and (b) comprised the largest homogeneous patient groups in our study settings.

![The process of selection and grouping of inpatients admitted to medicine departments of the teaching hospital (TH) and the non-teaching hospital (NTH) based on their diagnosis.](bmjopen-2016-012974f01){#BMJOPEN2016012974F1}

These groups were further divided into four subgroups to identify and analyse the patients exclusively having non-bacterial diagnoses corresponding to our study aim. Cardiovascular group (group a) was divided into two subgroups: 'cardiovascular diseases with no registered bacterial infection' (subgroup 1) and 'cardiovascular diseases with suspected bacterial infection' (subgroup 2). Similarly, the non-bacterial fever group (group b) was divided into 'malaria or viral fever with no registered bacterial infection' (subgroup 3) and 'malaria or viral fever with suspected bacterial infection' (subgroup 4, [figure 1](#BMJOPEN2016012974F1){ref-type="fig"}).

All patients with rheumatic heart disease (RHD) were categorised in subgroup 2 or in subgroup 4 to rule out all possible bacterial infection as a confounder, since the WHO guidelines for secondary prevention after rheumatic fever set the duration of preventive antibiotic treatment from 5 years up to lifelong, depending on a number of factors---for example, time since the last episode of rheumatic fever and severity of valve engagement, and support an individual assessment of every case.[@R22] [@R23]

An antibiotic prescribed for a day was considered as one prescribing occasion. Prescribed DDDs were calculated per 1000 patients. According to WHOCC, oral metronidazole (P01AB01) is coded as an antiprotozoal drug, but is coded as an antibacterial agent in the NLEMI. Therefore it was considered as an antibacterial agent in this study.[@R18]

Ethics statement {#s3d}
----------------

Being an observational study, the data collection did not interfere with the treatment or cause any additional risks for the patients. Moreover, the names of the prescribers were not recorded to minimise the effect of being observed. All patients were assigned a unique code during the data entry to maintain anonymity of the inpatients. This unique code was used to compare details of patient information and antibiotic prescriptions for the analysis. The data were collected at the individual level for all inpatients and were linked to each patient with the assigned unique codes instead of, for example, social security number. However, the analysis was conducted at group level to maintain confidentiality.

The ethics committee of Ruxmaniben Deepchand Gardi Medical College, Ujjain, approved the study with approval number: 41/2007.

Statistical methods {#s3e}
-------------------

All frequencies and percentage of categorical values were calculated. Sum, median, mean, range and SD were calculated for continuous numerical values. Values were rounded to the closest whole number for percentage, prescription tables and in the text. The independent t-test was used for comparison of normally distributed and continuous variables. The χ^2^ test was used for comparison of categorical values. Fisher\'s exact test was used for expected values \<5 and Pearson\'s χ^2^ test was used for expected values \>5. Bonferroni\'s correction for multiple comparisons was used and p values \<0.001 were chosen for significance level to minimise the risks of type one errors. The data were analysed with Excel, SPSS V.22 (SPSS, Chicago, Illinois, USA) and STATA V.13.1 (Stata Corp, College Station, Texas, USA).

Results {#s4}
=======

During the study period, a total of 21 557 patients were admitted to the two medicine departments, 7176 patients to the TH and 14 381 to the NTH ([figure 1](#BMJOPEN2016012974F1){ref-type="fig"}). Of those admitted, records of 20 patients were incomplete, 949 (4%) stayed less than one night and 285 patients (1%) were aged \<15 years. Therefore, in accordance with the inclusion criteria, 1254 patient records were excluded and 20 303 (94%) records were included for further analysis (6961 at the TH and 13 342 at the NTH, [figure 1](#BMJOPEN2016012974F1){ref-type="fig"}).

The most common diagnoses in the TH were COPD (10%), viral fever (7%) and hypertension (5%) and in the NTH were viral fever (10%), malaria (6%) and COPD (5%, [table 1](#BMJOPEN2016012974TB1){ref-type="table"}). Antibiotics were prescribed to 4540/6961 inpatients (65%) in the TH and 8900/13 342 (67%) in the NTH ([table 2](#BMJOPEN2016012974TB2){ref-type="table"}). An average of eight and five prescribing occasions were found per patient at the TH and NTH, respectively. Overall, a significantly higher proportion of the antibiotics prescribed in the TH adhered to the NLEMI: 77% prescriptions (27 640/35 732) than in the NTH: 60% (24 683/41 068, p\<0.001).

###### 

Number of inpatients in four diagnoses Subgroups at medicine departments of one teaching and one non-teaching hospital in Ujjain, India

  Cardiovascular with no registered bacterial infection Subgroup 1   Cardiovascular with suspected bacterial infection Subgroup 2   Malaria or viral fever with no registered bacterial infection Subgroup 3   Malaria or viral fever with suspected bacterial infection Subgroup 4                                                                                                                                             
  ------------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------- ---------- -------------------------------------------- -------------- -------------- ------------------------------ --------- --------
  **Total**                                                          **1068**                                                       **1738**                                                                   **Total**                                                              **438**    **254**    **Total**                                    **693**        **1177**       **Total**                      **55**    **28**
  Hypertension                                                       328 (31)                                                       470 (27)                                                                   COPD                                                                   209 (48)   77 (30)    **Malaria**                                  **237 (34)**   **872 (74)**   COPD                           10 (18)   5 (18)
  Cerebrovascular accident                                           126 (12)                                                       383 (22)                                                                   Rheumatic heart disease                                                130 (30)   102 (40)   Cerebral malaria caused by *P. falciparum*   4 (1)          11 (1)         Urinary tract infection        5 (9)     7 (25)
  Acute myocardial infarction                                        28 (3)                                                         202 (12)                                                                   Pulmonary tuberculosis                                                 19 (4)     18 (7)     Malaria caused by *P. falciparum* UNS        9 (1)          9 (1)          Typhoid fever                  8 (15)    2 (7)
  Chronic ischaemic heart disease                                    17 (2)                                                         189 (11)                                                                   Urinary tract infection                                                17 (4)     15 (6)     Malaria caused by *P. vivax* UNS             16 (2)         61 (5)         Acute gastroenteritis          4 (7)     6 (21)
  Coronary artery disease                                            98 (9)                                                         101 (6)                                                                    Acute gastroenteritis                                                  14 (3)     12 (5)     Malaria UNS                                  208 (30)       791 (67)       Disease of airways UNS         8 (15)    0 (0)
  Left ventricle failure                                             44 (4)                                                         69 (4)                                                                     Lower airway infection UNS                                             13 (3)     0 (0)      **Viral fever**                              **456 (66)**   **305 (26)**   Disease of upper airways UNS   7 (13)    0 (0)
  Congestive heart failure                                           56 (5)                                                         39 (2)                                                                     Sepsis                                                                 0 (0)      5 (2)                                                                                 Pulmonary tuberculosis         4 (7)     2 (7)
  Dilated cardiomyopathy                                             79 (7)                                                         6 (\<1)                                                                    HIV with infection                                                     8 (2)      1 (\<1)                                                                               HIV with infection             2 (4)     0 (0)
  Unspecified cardiomyopathy                                         21 (2)                                                         54 (3)                                                                     Rheumatic fever                                                        1 (\<1)    4 (2)                                                                                 Rheumatic heart disease        2 (4)     1 (4)
  Multiple valve disease                                             61 (6)                                                         7 (\<1)                                                                    Endocarditis                                                           0 (0)      4 (2)                                                                                 Pelvic inflammatory disease    2 (4)     0 (0)
  Angina pectoris                                                    10 (1)                                                         35 (2)                                                                     Pneumonia                                                              1 (\<1)    4 (2)                                                                                 Pneumonia                      0 (0)     1 (4)
  Acute ischaemic heart disease                                      31 (3)                                                         11 (1)                                                                     Others                                                                 26 (6)     12 (5)                                                                                Other diagnoses                3 (5)     4 (14)
  Deep vein thrombosis UNS                                           13 (1)                                                         19 (1)                                                                                                                                                                                                                                                                                      
  Mitral stenosis                                                    21 (2)                                                         2 (\<1)                                                                                                                                                                                                                                                                                     
  Hypertensive heart disease                                         20 (2)                                                         1 (\<1)                                                                                                                                                                                                                                                                                     
  Cardiac arrest                                                     2 (\<1)                                                        16 (1)                                                                                                                                                                                                                                                                                      
  Other                                                              113 (11)                                                       134 (8)                                                                                                                                                                                                                                                                                     

Bold presents total number of patients in the diagnosis group.

COPD, chronic obstructive pulmonary disease; NTH, non-teaching hospital; *P*, *Plasmodium*; TH, teaching hospital; UNS, unspecified.

###### 

Demographic details and antibiotic prescribing information of the inpatients in the medicine departments of one teaching and one non-teaching hospital in Ujjain, India

                                                Medicine department   Cardiovascular with no registered bacterial diagnosis Subgroup 1   Cardiovascular with suspected bacterial infection Subgroup 2   Malaria or viral fever with no registered bacterial diagnosis Subgroup 3   Malaria or viral fever with suspected bacterial infection Subgroup 4                                                                                                             
  --------------------------------------------- --------------------- ------------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------- ---------- ---------- ------------- ---------- ---------- ------------- --------- --------- ---------
  Inpatients, n                                 6961                  13 342                                                                                                                            1068                                                                       1738                                                                                 438        254                      693        1177                     55        28        
  Age (years), mean (SD)                        45 (17)               43 (18)                                                            **\<0.001**                                                    53 (14)                                                                    55 (15)                                                                **\<0.001**   49 (17)    51 (17)    0.222         36 (15)    35 (16)    0.387         37 (14)   40 (20)   0.440
  Inpatients prescribed ABs, n (%)              4540 (65)             8900 (67)                                                          0.034                                                          392 (37)                                                                   808 (46)                                                               **\<0.001**   299 (68)   179 (70)   0.545         569 (82)   831 (71)   **\<0.001**   53 (96)   21 (75)   0.006\*
  Duration of hospital stay (days), mean (SD)   6 (5)                 3 (3)                                                              **\<0.001**                                                    6 (5)                                                                      3 (3)                                                                  **\<0.001**   7 (5)      4 (3)      **\<0.001**   4 (4)      3 (2)      **\<0.001**   5 (3)     4 (2)     0.796
  Duration of AB treatment (days), mean (SD)    6 (4)                 4 (2)                                                              **\<0.001**                                                    6 (4)                                                                      4 (2)                                                                  **\<0.001**   7 (4)      4 (2)      **\<0.001**   5 (3)      4 (2)      **\<0.001**   5 (2)     5 (2)     0.419
  Total AB prescription, n                      35 732                41 068                                                                                                                            2741                                                                       3366                                                                                 2388       855                      3210       3451                     316       128       
  Prescriptions per patient                     7.9                   4.6                                                                                                                               7                                                                          4                                                                                    8          4.8                      5.6        4.2                      6         6.1       
  AB prescriptions by generic name, n (%)       2341 (7)              685 (2)                                                            **\<0.001**                                                    175 (6)                                                                    47 (1)                                                                 **\<0.001**   282 (12)   46 (5)     **\<0.001**   61 (2)     52 (2)     0.214         19 (6)    5 (4)     0.374\*
  Prescriptions of AB found in NLEMI, n (%)     27 640 (77)           24 683 (60)                                                        **\<0.001**                                                    --                                                                         --                                                                     --            --         --         --            --         --         --            --        --        --

Significant p values are shown in bold. Independent sample t-test was used to compare age, duration of hospital stay and duration of antibiotic treatment. Pearson χ^2^ was used to compare prescription details with expected value \>5.

\*Fisher's exact test was used to compare expected values \<5.

AB, antibiotics; NLEMI, National List of Essential Medicines of India; n (%), number of patients (percentage); NTH, non-teaching hospital; SD, standard deviation; TH, teaching hospital.

Seven per cent of antibiotics in the TH were prescribed using generic names, which was significantly higher than in the NTH (2%, p\<0.001). Some antibiotics were prescribed using trade names at the TH---for example, 'Cipro', 'Doxy', 'Genta' and 'Metrogyl'. However, these were local abbreviations devised by the staff for ciprofloxacin, doxycycline, gentamycin and metronidazole, respectively. Even though these four antibiotics were prescribed using trade names, generic antibiotics were dispensed from the hospital pharmacy. A longer duration of stay and longer duration of antibiotic treatment was observed at the TH (mean days: 6 and 6, respectively) than at the NTH (mean days: 3 and 4, respectively, p\<0.001).

Distribution of inpatients in groups (a) and (b) and antibiotic prescription patterns {#s4a}
-------------------------------------------------------------------------------------

Cardiovascular diseases accounted for 48% of patients in group (a) and (b) at the TH and 30% at the NTH. In the non-bacterial fever group, malaria was significantly more common at the NTH (74%) and viral fever was significantly more common at the TH (66%, p\<0.001, [table 1](#BMJOPEN2016012974TB1){ref-type="table"}).

Broad-spectrum antibiotics such as third-generation cephalosporins (J01DD) and FDCs (J01RA\*) comprised 52% of the prescribing occasions at the NTH, of which FDCs accounted for approximately half ([table 3](#BMJOPEN2016012974TB3){ref-type="table"}). These classes accounted for 13% of total prescribing occasions and \<1% FDCs. At the NTH, cephalosporins (third-generation cephalosporins J01DD, \>30%) were most commonly prescribed for the cardiovascular diseases (\>35%), followed by FDCs (\>20%). Fluoroquinolones (J01M) was the most commonly prescribed antibiotic class in the TH in both (a) and (b) groups (\>30% and \>40%, respectively).

###### 

Distribution of prescribed antibiotics according to class in four selected diagnoses groups at one teaching and one mon-teaching hospital in Ujjain, India

                                                               Cardiovascular with no registered bacterial infection Subgroup 1   Cardiovascular with suspected bacterial infection Subgroup 2   Malaria or viral fever with no registered bacterial infection Subgroup 3   Malaria or viral fever with suspected bacterial infection Subgroup 4                                                                                       
  ------------------------------------------------------------ ------------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------- ------------- ----------- ----------- ------------- ---------- --------- -------------
  Total prescriptions                                          2741                                                               3366                                                                                                                                      2388                                                                   855                      3210        3451                      316        128       
  Tetracyclines; J01A; J01AA                                   284 (10)                                                           5 (0)                                                          **\<0.001**                                                                243 (10)                                                               0 (0)                    553 (17)    75 (2)      **\<0.001**   83 (26)    0 (0)     
  β-Lactam ABs, penicillin; J01C                               456 (17)                                                           498 (15)                                                       0.041                                                                      622 (26)                                                               184 (22)   0.009         111 (3)     245 (7)     **\<0.001**   12 (4)     7 (5)     0.431
   Extended-spectrum penicillins; J01CA                        83 (3)                                                             99 (3)                                                         0.843                                                                      122 (5)                                                                99 (12)    **\<0.001**   19 (1)      51 (1)      **\<0.001**   0 (0)      2 (2)     
   Combination of penicillin including β-lactamase AB; J01CR   373 (14)                                                           399 (12)                                                       0.040                                                                      500 (21)                                                               85 (10)    **\<0.001**   92 (3)      194 (6)     **\<0.001**   12 (4)     5 (4)     1.0†
  Other β-lactams; J01D                                        496 (18)                                                           1391 (41)                                                      **\<0.001**                                                                353 (15)                                                               304 (36)   **\<0.001**   665 (21)    1792 (52)   **\<0.001**   40 (13)    39 (30)   **\<0.001**
   1st-generation cephalosporins; J01DB                        7 (0)                                                              16 (1)                                                         0.163                                                                      0 (0)                                                                  5 (1)                    0 (0)       9 (0)                     0 (0)      0 (0)     
   2nd-generation cephalosporins; J01DC                        0 (0)                                                              98 (3)                                                                                                                                    0 (0)                                                                  27 (3)                   0 (0)       168 (5)                   0 (0)      0 (0)     
   3rd-generation cephalosporins; J01DD                        481 (18)                                                           1254 (37)                                                      **\<0.001**                                                                353 (15)                                                               272 (32)   **\<0.001**   665 (21)    1606 (47)   **\<0.001**   40 (13)    39 (30)   **\<0.001**
   4th-generation cephalosporins; J01DH                        8 (0)                                                              23 (1)                                                         0.032                                                                      0 (0)                                                                  0 (0)                    0 (0)       9 (0)                     0 (0)      0 (0)     
  Sulfonamide with timethoprim; J01E: J01EE                    8 (0)                                                              0 (0)                                                                                                                                     18 (1)                                                                 0 (0)                    8 (0)       0 (0)                     0 (0)      0 (0)     
  Macrolides, lincosamides; J01F                               16 (1)                                                             2 (0)                                                          **\<0.001**                                                                4 (0)                                                                  6 (1)      0.025         15 (0)      7 (0)       0.060         3 (1)      4 (3)     0.110†
   Macrolides; J01FA                                           12 (0)                                                             2                                                              0.002                                                                      4 (0)                                                                  6 (1)                    15 (0)      7 (0)                     3 (1)      4 (3)     
   Lincosamides; J01FF                                         4 (0)                                                              0 (0)                                                                                                                                     0 (0)                                                                  0 (0)                    0 (0)       0 (0)                     0 (0)      0 (0)     
  Aminoglycoside; J01G: J01GB                                  78 (3)                                                             73 (2)                                                         0.090                                                                      149 (6)                                                                46 (5)     0.364         17 (1)      60 (2)      **\<0.001**   11 (3)     9 (7)     0.102
  Quinolones; J01M: J01MA                                      1031 (38)                                                          301 (9)                                                        **\<0.001**                                                                731 (31)                                                               112 (13)   **\<0.001**   1526 (48)   464 (13)    **\<0.001**   126 (40)   37 (29)   0.030
  Fixed-dose combination of ABs; J01R: J01RA\*                 12 (0)                                                             929 (28)                                                       **\<0.001**                                                                31 (1)                                                                 170 (20)   **\<0.001**   34 (1)      669 (19)    **\<0.001**   6 (2)      17 (13)   **\<0.01**
  Other ABs; J01X                                              167 (6)                                                            176 (5)                                                        0.145                                                                      132 (6)                                                                30 (4)     0.020         149 (5)     138 (4)     0.197         20 (6)     15 (12)   0.056
   Glycopetide ABs; J01XA                                      15 (1)                                                             176 (5)                                                        **\<0.001**                                                                0 (0)                                                                  0 (0)                    0 (0)       0 (0)                     0 (0)      0 (0)     
   Imidazole derivatives; J01XD                                152 (6)                                                            0 (0)                                                                                                                                     132 (6)                                                                30 (4)     0.020         149 (5)     137 (4)     0.176         20 (6)     15 (12)   0.056
   Other ABs; J01XX                                            0 (0)                                                              0 (0)                                                                                                                                     0 (0)                                                                  0 (0)                    0 (0)       1 (0)                     0 (0)      0 (0)     
  Drugs for treatment of tuberculosis; J04A                    0 (0)                                                              0 (0)                                                                                                                                     24 (1)                                                                 0 (0)                    0           0 (0)                     0 (0)      0 (0)     
   Antibiotics; J04AB (treatment for tuberculosis)             0 (0)                                                              0 (0)                                                                                                                                     6 (0)                                                                  0 (0)                    0 (0)       0 (0)                     0 (0)      0 (0)     
   Hydrazides; J04AC                                           0 (0)                                                              0 (0)                                                                                                                                     6 (0)                                                                  0 (0)                    0 (0)       0 (0)                     0 (0)      0 (0)     
   Other drugs for treatment of tuberculosis; J04AK            0 (0)                                                              0 (0)                                                                                                                                     12 (1)                                                                 0 (0)                    0 (0)       0 (0)                     0 (0)      0 (0)     
  Nitroimidazole derivatives; P01AB (oral metronidazole)       201 (7)                                                            0 (0)                                                                                                                                     81 (3)                                                                 3 (0)      **\<0.001**   132 (4)     1 (0)       **\<0.001**   15 (5)     0 (0)     

Significant p values shown in bold.

Pearson χ^2^ and

†Fisher's exact test was used to compare antibiotic prescribing details.

AB, antibiotics; ATC, Anatomical Therapeutic Chemical (classification); J01RA\*, ATC code as assigned by Sharma *et al*.[@R17] n (%), number of prescriptions (percentage in antibiotic class); NTH, non-teaching hospital; TH, teaching hospital.

Third-generation cephalosporins (J01DD) constituted 47% and 30% of the prescriptions in subgroup 3 and 4 at the NTH, followed by FDCs (19% and 29% of the prescriptions, respectively). Overall, antibiotic prescriptions were significantly more common for the patients in subgroup 3 than in the subgroup 1′ (p\<0.001). The type of malaria was verified by blood sample reports in some cases of subgroup 3 (TH: 4% and NTH: 7%). None of the records from the four subgroups showed a requisition for samples to be sent for bacterial culture and a susceptibility test.

Ciprofloxacin (J01MA02) was the most frequently prescribed antibiotic substance measured in DDD/1000 patients at the TH and ceftriaxone (J01DD04, [table 4](#BMJOPEN2016012974TB4){ref-type="table"}) at the NTH. The highest number of prescribed DDDs/1000 patients was recorded for ciprofloxacin, followed by doxycycline and ceftriaxone in both hospitals ([figure 2](#BMJOPEN2016012974F2){ref-type="fig"}).

###### 

Most commonly prescribed antibiotics among the selected diagnoses groups presenting the prescribing occasions in DDDs/1000 patients at sixth level of the ATC classification

                                         Cardiovascular with no registered bacterial infection (Subgroup 1) n (%)   Cardiovascular with suspected bacterial infection (Subgroup 2) n (%)   Malaria or viral fever with no registered bacterial infection (Subgroup 3) n (%)   Malaria or viral fever with suspected bacterial infection (Subgroup 4)n (%)                                             
  -------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------- ------------- ------------- ------------
  Total DDDs/1000 patients               2062 (99^\#^)                                                              1456 (100)                                                             4514 (99^\#^)                                                                      3421 (100†)                                                                   4480 (100†)   3048 (100†)   5432 (100†)   5827 (100)
  Doxycycline, J01AA02                   491 (24)                                                                                                                                          1030 (23)                                                                                                                                                        1463 (33)     296 (10)      2745 (51)     
  Ampicillin, J01CA01                    68 (3)                                                                                                                                            170 (4)                                                                                                                                                                                                    
  Amoxicillin, J01CA04                                                                                              81 (6)                                                                                                                                                    435 (13)                                                                                                                
  Amoxicillin+clavulanic acid, J01CR02                                                                                                                                                                                                                                        566 (17)                                                                                    88 (3)                      
  Piperacillin+tazobactam, J01CR05                                                                                                                                                                                                                                                                                                                                        34 (1)                      
  Ampicillin+cloxacillin, J01CR50        217 (11)                                                                                                                                          774 (17)                                                                                                                                                                                     191 (4)       
  Cefuroxime, J01DC02                                                                                                                                                                                                                                                         95 (3)                                                                                      136 (4)                     
  Cefprozil, J01DC10                                                                                                75 (5)                                                                                                                                                                                                                                                                            
  Cefotaxime, J01DD01                    172 (8)                                                                    46 (3)                                                                 298 (7)                                                                            59 (2)                                                                        199 (4)       96 (3)        295 (5)       
  Ceftriaxone, J01DD04                   133 (6)                                                                    558 (38)                                                               244 (5)                                                                            907 (27)                                                                      560 (13)      1052 (35)     164 (3)       1402 (24)
  Azithromycin, J01FA10                                                                                                                                                                                                                                                                                                                                                                               476 (8)
  Gentamicin, J01GB03                    44 (2)                                                                                                                                            167 (4)                                                                            81 (2)                                                                                                                  
  Amikacin, J01GB06                                                                                                                                                                                                                                                                                                                                                                                   321 (6)
  Ofloxacin, J01MA01                                                                                                                                                                                                                                                                                                                                                      202 (7)                     
  Ciprofloxacin, J01MA02                 687 (33)                                                                   141 (10)                                                               1057 (23)                                                                          527 (15)                                                                      1940 (43)     602 (20)      1185 (22)     2886 (50)
  Norfloxacin, J01MA06                                                                                                                                                                     201 (4)                                                                                                                                                                                      273 (5)       
  Levofloxacin, J01MA12                                                                                             73 (5)                                                                 202 (4)                                                                            129 (4)                                                                                                   145 (3)       
  Cefoperazone+sulbactam, J01RA\*83                                                                                 92 (6)                                                                                                                                                    94 (3)                                                                                      90 (3)                      125 (2)
  Ceftriaxone+sulbactam, J01RA\*84                                                                                  228 (16)                                                                                                                                                  277 (8)                                                                                     199 (7)                     
  Ceftriaxone+tazobactam, J01RA\*85                                                                                 162 (11)                                                                                                                                                  156 (5)                                                                                     162 (5)                     250 (4)
  Metronidazole, J01XD01                 139 (7)                                                                                                                                           262 (6)                                                                            95 (3)                                                                        204 (5)       91 (3)        262 (5)       367 (6)
  Metronidazole, P01AB01 (Oral)          111 (5)                                                                                                                                           109 (2)                                                                                                                                                          114 (3)                     172 (3)       

\#Total percentage of most commonly prescribed antibiotics is 99%.

†Rounding off the percentages to nearest integer made the total more than 100%.

ATC, Anatomical Therapeutic Chemical; DDD, defined daily dose; n (%), number of prescriptions (percentage); NTH, non-teaching hospital; TH, teaching hospital.

![Top 90% of prescription in the four selected groups measured in defined daily dose (DDD)/1000 patients, presented at fourth level of the Anatomical Therapeutic Chemical (ATC) classification at one teaching and one non-teaching hospitals in Ujjain, India. ABs, antibiotics; NTH, non-teaching hospital; TH, teaching hospital.](bmjopen-2016-012974f02){#BMJOPEN2016012974F2}

Discussion {#s5}
==========

To our knowledge this study is the first to investigate and present antibiotic prescription practices at medicine departments in Indian private sector hospitals by focusing on non-bacterial infectious diseases. This is a limitation, as the results of this study could not be compared with the findings of any other study. Thus the our results were compared with the most equivalent studies available globally.

Antibiotics were commonly prescribed to inpatients at both study hospitals. Irrespective of the indications, broad-spectrum antibiotics and third-generation cephalosporins, which should be conserved for high-risk comorbidities and life-threatening bacterial infections, were prescribed frequently. This study also highlights the high rates of antibiotic prescriptions used to treat selected groups of non-bacterial infectious diseases, such as cardiovascular disease, malaria and viral fever.

Antibiotic prescriptions in the cardiovascular and fever groups {#s5a}
---------------------------------------------------------------

The average percentages of patients who were prescribed antibiotics in the medicine departments were similar (TH: 65% and NTH: 67%, p\<0.001) in comparison with the rates in the medicine department of a public hospital at Bathalapalli, Andhra Pradesh, India (63%).[@R26] With a few exceptions, such as rheumatic fever, endocarditis, pericarditis and myocarditis (bacterial or viral), cardiovascular diseases are primarily non-infectious. COPD and RHD are diseases commonly found in patients with cardiovascular disease. Rheumatic fever is an immune response sequel to an infection and may cause endocarditis.[@R23] [@R27] However, pericarditis and myocarditis most commonly develop from viral pathogens, for which antibiotic treatment is not a routine recommendation.[@R28] [@R29]

Interestingly, more than 35% of inpatients among the 'cardiovascular group with no registered bacterial infection' were prescribed antibiotics at both hospitals. In accordance with treatment guidelines and recommendations, only patients who have a confirmed infectious diagnosis are expected to be given an antibiotic prescription.[@R30] Nonetheless, empirical or presumptive antibiotic therapy is also accepted when the clinical diagnosis, based on the presence of a strong clinical suspicion of bacterial infection, is substantiated by relevant medical history and clinical findings.[@R30] According to the WHO and the Indian National Treatment Guidelines for Antimicrobial Use, presumptive therapy is typically a one-time treatment given for clinically presumed infection while waiting for the culture report.[@R31] [@R32] A combination of the clinical findings---laboratory and radiological reports---is considered to confirm the diagnosis and lead to definitive treatment.[@R32]

Microbiology laboratories were highly underused in both study hospitals. None of the patient records in the selected four subgroups included notes about sending samples for culture and susceptibility testing. Therefore, the practice of prescribing antibiotics to patient groups with no registered bacterial infection in the absence of laboratory confirmation could not be considered to be rational. Among the patients with COPD and RHD, the aetiology of the current episode of hospitalisation could potentially be expected to be non-bacterial (eg, viral infection). However, this could not be confirmed owing to the absence of laboratory investigations. It is worth mentioning here that prolonged empirical antibiotic treatment without a clear evidence of infection is one of the causes of the development of antibiotic resistance.

More FDCs were prescribed to the cardiovascular patients at the NTH than at the TH. The rationality of the newer FDCs coded with ATC code: J01RA\* has not yet been established and these combinations are not listed in either the NLEMI or WHOLEM.[@R18] [@R19] It is also evident that the constituents of these combinations are often present in lower quantities than is recommended, which might lead to the development of antibiotic resistance.[@R33]

The subgroup 'malaria or viral fever with suspected bacterial infection' was found to have the highest rate of antibiotic prescriptions among all the four subgroups (TH: 96%, NTH: 75%). Our results also show that patients with fever were more likely to receive antibiotic prescriptions than patients with cardiovascular diseases. Fever is a common symptom of malaria, viral fever and bacterial infection. Therefore, the doctors might have prescribed antibiotics as a 'prophylactic' treatment to treat bacterial infection, if any. In our study the rate of antibiotic prescriptions for patients with fever was higher than, yet comparable to, a study at primary and secondary healthcare settings in Uttar Pradesh, India, where 85% of the patients with fever were prescribed antibiotics.[@R34] Additionally, in our study a high percentage of patients with fever (malaria or viral fever) with 'no registered bacterial infection' were prescribed antibiotics (TH: 82%, NTH: 71%). An outpatient study from Uganda, a malaria-endemic country, showed that 42% of patients with malaria were prescribed antibiotics without any registered indication.[@R25] As the majority of the prescriptions in our study were empirical, the rationale for using the antibiotics cannot be evaluated. However, prescribing antibiotics to treat non-bacterial infections is considered to be an irrational practice. Thus it is imperative that this matter be addressed.

Adherence to the essential medicine lists and prescriptions by generic name {#s5b}
---------------------------------------------------------------------------

A higher proportion of prescribed antibiotics at the TH (77%) than at the NTH (60%) were from the NLEMI (p\<0.001). This might be attributable to a management policy at the TH to purchase and supply medicines. However, there is a need to improve adherence to the NLEMI at both hospitals. According to WHO, prescribing drugs by their generic name is part of rational prescribing, is cost-effective and provides flexibility, allowing purchase of the drug from any company. This policy is equally applicable to both public and private healthcare settings. However, adherence to this policy is greater at public hospitals, followed by 'private non-profit' hospitals and by the 'private for-profit' hospitals.[@R13] [@R14] [@R35]

In our study, a significantly lower proportion of antibiotic prescriptions were made by generic name for the patients of subgroup 1 (TH: 6%, NTH: 1% p\<0.001) or subgroup 2 (TH: 12% NTH: 5% p\<0.001) at the NTH than at the TH. Third-generation cephalosporins (J01D, 29%) and FDCs (J01RA\*, 23%) were the most commonly prescribed classes of antibiotics at the NTH, whereas quinolones were most commonly prescribed at the TH (J01M, 37%, NTH: 13%). Previous studies from Uttar Pradesh, India and Madhya Pradesh, India have also shown similar results for academic and non-academic hospitals.[@R13] [@R14] [@R17] The high incidence of prescribing these classes is further supported by Van Boeckel *et al*, who observed a significant increase in the consumption of fluoroquinolones and cephalosporins globally over the past decade. This increase was mainly attributed to the increased rates in India and China.[@R9]

At the NTH, prescriptions of FDCs varied between 19% and 28% among the selected subgroups (TH: \<2%) and the prescriptions of third-generation cephalosporins varied between 30% and 47% (TH: \<22%). According to WHO, prescribing multiple antibiotics when not indicated, often combined in inadequate doses (smaller or larger quantity than recommended), and prescription of drugs other than local or national guidelines are all examples of actions deemed inappropriate.[@R36] All these practices could be seen in prescribing newer FDCs (J01RA\*); both of the study hospitals are from the private sector and are regulated by the same trust on a 'not for-profit' basis. The differences in the prescribing practices might be due to each hospital\'s policy and because academic hospitals are part of the educational process, and regular educational activities conducted at these hospitals result in better adherence to the guidelines, as seen at the TH.

Another reason for the frequent prescribing of broad-spectrum antibiotics, new FDCs and use of trade names at the NTH could be explained by the results of a review conducted by Blumenthal.[@R37] That review concluded that physicians who had received gifts or money from pharmaceutical companies were more likely to prescribe drugs by brand names and less likely to use the generic names. The pressure on doctors at the NTH might be expected, owing to unrestricted visits from pharmaceutical company representatives.[@R37] Moreover, these new FDCs of antibiotics are more expensive than the regular and generic formulations.[@R13] [@R14] [@R37] Restriction of these visits and management control over the purchase and supply of medicines are probably the main reasons for the low incidence of prescribing FDCs and the high use of generic drugs at the TH.

Interestingly, trade names were used as local abbreviations to prescribe the four most commonly prescribed antibiotics: ciprofloxacin, doxycycline, gentamycin and metronidazole, at the TH, as discussed in the 'Results' section. However, only generic drugs were purchased and dispensed at the TH owing to administrative control over the purchase and supply of the drugs. Thus even if these antibiotics were prescribed using an abbreviation similar to the trade name, they were included in the generic name prescribing category.

Duration of hospital stay and of antibiotic treatment {#s5c}
-----------------------------------------------------

In this study both the duration of hospital stay and the duration of antibiotic treatment were longer at the TH than the NTH among all inpatients groups, possibly because patients at the TH received free healthcare services and drugs, making their stay economically feasible. In contrast, at the NTH, patients had to pay for all the services and drugs they received. This association of longer duration of stay and antibiotic treatment at TH has also been found in previous studies from India.[@R13] [@R14] [@R17] However, it is evident that treatment given for a period that is either shorter or longer than recommended, is inappropriate, and contributes substantially to the development of antibiotic resistance.[@R1] [@R36]

The absence of computerised record systems in hospitals and of personal identification numbers, untrained staff and high staff turnover make a detailed study like this time consuming and onerous and delays the analysis. We are aware that extensive manual checking and adding the ICD codes and ATCs for the new FDCs to the data have prolonged the analysis and delayed the presentation. However, use of man power is the only option to conduct such detailed studies at resource constrained settings but at the same time leads to a more accurate description of the prescribing patterns.

Strengths and limitations {#s6}
-------------------------

A large number of patients were screened over a 3-year period; this obviates seasonal variations in infectious aetiology, which would affect antibiotic prescribing. The same form was used for the data collection and the process was supervised and monitored by same person at both hospitals to improve the reliability of the data. The diagnoses were not verified externally, which is a limitation of the study. However, external verification is virtually inapplicable to studies that rely upon the routine collection of data. The results of the study were based on the notes included in the patient files. Extensive efforts were made to document all notes, including diagnoses written in the patient files. However, the possibility that a few diagnoses were missed and some data lost during the transition from the forms to digital storage cannot be excluded.

Conclusion {#s7}
==========

A greater number of prescribing occasions were recorded at the TH, but not at the NTH, than advised by the guidelines. However, overall adherence was low. Fever was a factor leading to antibiotic prescription at both hospitals. Patients with non-bacterial infections, such as malaria or viral fever, or with cardiovascular diseases were prescribed antibiotics at both medicine departments, which could not be justified. Broad-spectrum antibiotics with irrational combinations of antibiotics were commonly prescribed in the study hospitals for non-indicated conditions. A large proportion of patients were categorised as having suspected bacterial diagnoses (subgroups 2 and 4). If microbiology reports could have confirmed the aetiology, some of these might have been categorised in the non-bacterial group and might have contributed to higher antibiotic prescribing rates in the non-bacterial diagnoses (subgroups 1 and 3). However, this was not possible owing to the absence of confirmed aetiology and the nature of the study design (observational).

Generalisability and future implications {#s8}
========================================

The data collection method used in the study is robust and reliable. In accordance with one of the WHO goals of the 'Global Action Plan' and in view of limited knowledge of antibiotic use and resistance patterns, our study suggests that there is a need to conduct similar long-term surveillance studies globally and share the results. The data collection method and tested tool used in the study could easily be adapted in other settings that lack computerised patient records. The management at the TH had a policy of controlling the purchase and supply of medicines. This control had a positive effect at the TH in comparison with the NTH, minimising antibiotic prescribing and resulting in better adherence to the NLEMI and the use of generic names. This control could be implemented and tested in other constrained settings. The recruitment of nursing staff who routinely work in the department for manual data collection would have helped to minimise the influence on the prescribers. High prescribing rates of antibiotics and use of FDCs among inpatients in these settings are broadly representative of practices of similar healthcare settings in low--middle income countries. Another important issue raised in the study is lack of use of microbiology facilities for culture and susceptibility testing, which is of utmost importance. The need to develop and implement local diagnosis-specific prescribing guidelines in conjunction with continuous follow-up is also emphasised by our study. Physicians should be motivated to send samples for culture before prescribing antibiotics. Improving hygiene practices is another recommendation that would prevent the spread of infection and reduce the 'prophylactic' use of antibiotics.
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